Search

Your search keyword '"Imus, Philip H."' showing total 36 results
Start Over Author "Imus, Philip H."
36 results on '"Imus, Philip H."'

4. Allogeneic blood or marrow transplantation using haploidentical grandchildren donors and post‐transplant cyclophosphamide‐based graft‐versus‐host disease prophylaxis.

Author

Aljawai, Yosra M., Tsai, Hua‐Ling, Varadhan, Ravi, Jones, Richard J., and Imus, Philip H.

Subjects
PROPENSITY score matching, CELL transplantation, OLDER patients, OVERALL survival, GRANDCHILDREN, HEMATOPOIETIC stem cell transplantation, STEM cell transplantation
Abstract

Summary: Background: High‐dose post‐transplant cyclophosphamide allows safe and effective use of allografts from haploidentical relatives (siblings, parents and children) in patients undergoing allogeneic blood or marrow transplant (alloBMT). More recently, second‐ and third‐degree relatives have also been shown to be safe allograft donors. An increasing number of older patients undergoing alloBMT have been receiving allografts from haploidentical donors. However, older patients are more likely to have older siblings and children, and older donor age is associated with worse outcomes. Objective: In the current study, we report the safety and utility of grandchildren as haploidentical donors and compared with children as donors in patients undergoing alloBMT. Methods: We compared characteristics and outcomes of alloBMT patients aged 55 years and older with children older than 30 years as donors (C group; n = 276) and those with grandchildren as donors (GC group; n = 40). Because many important baseline characteristics predict outcomes after alloBMT, we performed propensity score matched analysis based on recipient age, alloBMT year, disease, graft source and haematopoietic cell transplantation comorbidity index (HCT‐CI). Results: The median age of recipients was 67 years (range 55–79) in the C group and 73 years (range 57–78) in the GC group. More than 70% of recipients in the GC group were older than 70 years, compared with 27% in the C group. The median donor age was 37 years (range 31–52) in the C group and 20 years (range 14–34) in the GC group. More patients in the GC group had HCT‐CI scores ≥3 than in the C group (32.5% vs. 23%, p = 0.27). Two‐year overall survival did not differ between the two groups (GC 62% vs. C 60%, hazard ratio [HR] 0.96, 95% confidence interval [CI] 0.53–1.75, p = 0.90) despite recipients of allografts from grandchildren being older. The 2‐year RFS was 55% in the C group compared with 50% in the GC group (HR 1.05, 95% CI 0.62–1.77, p = 0.85). Non‐relapse mortality subdistribution [SD] (SDHR 1.36, 95% 0.70–2.63, p = 0.36), relapse (SDHR 0.72, 95% CI 0.33–1.58, p = 0.42) or relapse‐free survival (HR 1.05, 95% CI 0.62–1.77, p = 0.85). Propensity score matching analysis showed no significant differences in 2‐year overall survival (GC 64% vs. C 53%; HR 0.77, 95% CI 0.42–1.42, p = 0.40), non‐relapse mortality (SDHR 1.26, 95% 0.66–2.41, p = 0.48), relapse (SDHR 0.57, 95% CI 0.21–1.52, p = 0.26) or relapse‐free survival (HR 0.94, 95% CI 0.57–1.54, p = 0.81). Conclusion: Our results indicate that outcomes of alloBMT patients with grandchild donors are similar to those with child donors, despite recipients' older age and higher comorbidities in the GC group. Grandchildren should be considered when selecting a donor for older alloBMT recipients. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

5. Thrombotic Microangiopathy after Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis

Author

Imus, Philip H., Tsai, Hua-Ling, DeZern, Amy E., Jerde, Kevin, Swinnen, Lode J., Bolaños-Meade, Javier, Luznik, Leo, Fuchs, Ephraim J., Wagner-Johnston, Nina, Huff, Carol Ann, Gladstone, Douglas E., Ambinder, Richard F., Gocke, Christian B., Ali, Syed Abbas, Borrello, Ivan M., Varadhan, Ravi, Brodsky, Robert, and Jones, Richard J.

Published
2020
Full Text
View/download PDF

6. Allogeneic transplantation for Ph+ acute lymphoblastic leukemia with posttransplantation cyclophosphamide

Author

Webster, Jonathan A., Luznik, Leo, Tsai, Hua-Ling, Imus, Philip H., DeZern, Amy E., Pratz, Keith W., Levis, Mark J., Gojo, Ivana, Showel, Margaret M., Prince, Gabrielle, Bolaños-Meade, Javier, Gondek, Lukasz P., Ghiaur, Gabriel, Dalton, W. Brian, Jain, Tania, Fuchs, Ephraim J., Gladstone, Douglas E., Gocke, Christian B., Ali, Syed Abbas, Huff, Carol Ann, Borrello, Ivan M., Swinnen, Lode, Wagner-Johnston, Nina, Ambinder, Richard F., Jones, Richard J., and Smith, B. Douglas

Published
2020
Full Text
View/download PDF

7. Allogeneic Blood or Marrow Transplantation with Post-Transplantation Cyclophosphamide for Peripheral T Cell Lymphoma: The Importance of Graft Source

Author

Sterling, Cole H., Hughes, Michael S., Tsai, Hua-Ling, Yarkony, Kathryn, Fuchs, Ephraim J., Swinnen, Lode J., Paul, Suman, Bolaños-Meade, Javier, Luznik, Leo, Imus, Philip H., Ali, Syed Abbas, Jain, Tania, Ambinder, Alexander, DeZern, Amy, Huff, Carol Ann, Gocke, Christian B., Varadhan, Ravi, Wagner-Johnston, Nina, Jones, Richard J., and Ambinder, Richard F.

Published
2023
Full Text
View/download PDF

8. Allogeneic Blood or Marrow Transplantation with High-Dose Post-Transplantation Cyclophosphamide for Acute Lymphoblastic Leukemia in Patients Age ≥55 Years

Author

Webster, Jonathan A., Reed, Madison, Tsai, Hua-Ling, Ambinder, Alexander, Jain, Tania, Dezern, Amy E., Levis, Mark J., Showel, Margaret M., Prince, Gabrielle T., Hourigan, Christopher S., Gladstone, Douglas E., Bolanos-Meade, Javier, Gondek, Lukasz P., Ghiaur, Gabriel, Dalton, W. Brian, Paul, Suman, Fuchs, Ephraim J., Gocke, Christian B., Ali, Syed Abbas, Huff, Carol Ann, Borrello, Ivan M., Swinnen, Lode, Wagner-Johnston, Nina, Ambinder, Richard F., Luznik, Leo, Gojo, Ivana, Smith, B. Douglas, Varadhan, Ravi, Jones, Richard J., and Imus, Philip H.

Published
2023
Full Text
View/download PDF

12. Major Histocompatibility Mismatch and Donor Choice for Second Allogeneic Bone Marrow Transplantation

Author

Imus, Philip H., Blackford, Amanda L., Bettinotti, Maria, Iglehart, Brian, Dietrich, August, Tucker, Noah, Symons, Heather, Cooke, Kenneth R., Luznik, Leo, Fuchs, Ephraim J., Brodsky, Robert A., Matsui, William H., Huff, Carol Ann, Gladstone, Douglas, Ambinder, Richard F., Borrello, Ivan M., Swinnen, Lode J., Jones, Richard J., and Bolaños-Meade, Javier

Published
2017
Full Text
View/download PDF

13. Nonmyeloablative, HLA-Mismatched Unrelated Peripheral Blood Transplantation with High-Dose Post-Transplantation Cyclophosphamide

Author

Rappazzo, Katherine C., Zahurak, Marianna, Bettinotti, Maria, Ali, Syed Abbas, Ambinder, Alex J., Bolaños-Meade, Javier, Borrello, Ivan, Dezern, Amy E., Gladstone, Doug, Gocke, Christian, Fuchs, Ephraim, Huff, Carol Ann, Imus, Philip H., Jain, Tania, Luznik, Leo, Rahmat, Leena, Swinnen, Lode J., Wagner-Johnston, Nina, Jones, Richard J., and Ambinder, Richard F.

Published
2021
Full Text
View/download PDF

14. Allogeneic Blood or Marrow Transplantation with Nonmyeloablative Conditioning and High-Dose Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis for Secondary Central Nervous System Lymphoma

Author

Sterling, Cole H., Tsai, Hua-Ling, Holdhoff, Matthias, Bolaños-Meade, Javier, Luznik, Leo, Fuchs, Ephraim J., Huff, Carol Ann, Gocke, Christian B., Ali, Syed Abbas, Borrello, Ivan M., Varadhan, Ravi, Jones, Richard J., Gladstone, Douglas E., Ambinder, Richard F., Wagner-Johnston, Nina, Swinnen, Lode J., and Imus, Philip H.

Published
2021
Full Text
View/download PDF

15. BCMA CAR T cells: the winding path to success

Author

Borrello, Ivan and Imus, Philip H.

Subjects
Antigens, Axicabtagene ciloleucel, B cells, T cells, Health care industry
Abstract

Chimeric antigen receptor (CAR) T cells have been shown to successfully treat some hematopoietic malignancies. Recognition of a relevant target on malignant cells and the proper costimulatory molecule are essential for CAR T cell efficacy. In this issue of theJCI, Cohen et al. conducted an early phase trial to evaluate B cell maturation antigen-targeting (BCMA-targeting) CAR T cells in patients with refractory multiple myeloma. Patients who received the highest dose of BCMA-targeting CAR T cells in combination with lymphodepletion had the greatest response. The results of the study provide further support for the use of BCMA-targeting CAR T cells for myeloma, and reiterate the importance of space and cell dose for CAR T cell success., CAR T cell therapy for myeloma The impressive success of CD19-targeted chimeric antigen receptor (CAR) T cell therapy for both pediatric acute lymphoblastic leukemia (ALL) and adult diffuse large cell [...]

Published
2019
Full Text
View/download PDF

17. Allogeneic Blood or Marrow Transplantation with Post-Transplantation Cyclophosphamide for Peripheral T Cell Lymphoma: The Importance of Graft Source

Author

Sterling, Cole H., primary, Hughes, Michael S., additional, Tsai, Hua-Ling, additional, Yarkony, Kathryn, additional, Fuchs, Ephraim J., additional, Swinnen, Lode J., additional, Paul, Suman, additional, Bolaños-Meade, Javier, additional, Luznik, Leo, additional, Imus, Philip H., additional, Ali, Syed Abbas, additional, Jain, Tania, additional, Ambinder, Alexander, additional, DeZern, Amy, additional, Huff, Carol Ann, additional, Gocke, Christian B., additional, Varadhan, Ravi, additional, Wagner-Johnston, Nina, additional, Jones, Richard J., additional, and Ambinder, Richard F., additional

Published
2022
Full Text
View/download PDF

18. Allogeneic Blood or Marrow Transplantation with High-Dose Post-Transplantation Cyclophosphamide for Acute Lymphoblastic Leukemia in Patients Age ≥55 Years

Author

Webster, Jonathan A., primary, Reed, Madison, additional, Tsai, Hua-Ling, additional, Ambinder, Alexander, additional, Jain, Tania, additional, Dezern, Amy E., additional, Levis, Mark J., additional, Showel, Margaret M., additional, Prince, Gabrielle T., additional, Hourigan, Christopher S., additional, Gladstone, Douglas E., additional, Bolanos-Meade, Javier, additional, Gondek, Lukasz P., additional, Ghiaur, Gabriel, additional, Dalton, W. Brian, additional, Paul, Suman, additional, Fuchs, Ephraim J., additional, Gocke, Christian B., additional, Ali, Syed Abbas, additional, Huff, Carol Ann, additional, Borrello, Ivan M., additional, Swinnen, Lode, additional, Wagner-Johnston, Nina, additional, Ambinder, Richard F., additional, Luznik, Leo, additional, Gojo, Ivana, additional, Smith, B. Douglas, additional, Varadhan, Ravi, additional, Jones, Richard J., additional, and Imus, Philip H., additional

Published
2022
Full Text
View/download PDF

20. Allogeneic Blood or Marrow Transplantation (AlloBMT) with High-Dose Post-Transplantation Cyclophosphamide (PTCy) for Acute Lymphoblastic Leukemia (ALL) in Patients Aged ≥ 55: Best Results in B ALL in First Remission (CR1) with Reduced-Intensity Conditioning (RIC)

Author

Webster, Jonathan Allen, primary, Reed, Madison C., additional, Tsai, Hua-Ling, additional, Ambinder, Alexander J., additional, Jain, Tania, additional, DeZern, Amy E., additional, Levis, Mark J., additional, Showel, Margaret M., additional, Prince, Gabrielle T., additional, Hourigan, Christopher S., additional, Bolaños-Meade, Javier, additional, Gondek, Lukasz P., additional, Ghiaur, Gabriel, additional, Dalton, William Brian, additional, Paul, Suman, additional, Fuchs, Ephraim J., additional, Gocke, Christian B., additional, Ali, Abbas Abbas, additional, Gladstone, Douglas E., additional, Huff, Carol Ann, additional, Borrello, Ivan M., additional, Swinnen, Lode J., additional, Wagner-Johnston, Nina D., additional, Ambinder, Richard F., additional, Luznik, Leo, additional, Gojo, Ivana, additional, Smith, B. Douglas Douglas, additional, Varadhan, Ravi, additional, Jones, Richard J., additional, and Imus, Philip H., additional

Published
2022
Full Text
View/download PDF

21. Mismatched donor transplantation with post-transplantation cyclophosphamide for advanced cutaneous T-cell lymphoma: a single-center retrospective study

Author

Hughes, Michael S., primary, Sterling, Cole H., additional, Varadhan, Ravi, additional, Ambinder, Richard F., additional, Jones, Richard J., additional, Sweren, Ronald J., additional, Rozati, Sima, additional, Bolaños-Meade, Javier, additional, Luznik, Leo, additional, Imus, Philip H., additional, Ali, Syed Abbas, additional, Borrello, Ivan M., additional, Huff, Carol Ann, additional, Jain, T., additional, Ambinder, Alexander, additional, DeZern, Amy E., additional, Gocke, Christian B., additional, Gladstone, Douglas E., additional, Swinnen, Lode J., additional, Wagner-Johnston, Nina D., additional, and Fuchs, Ephraim J., additional

Published
2022
Full Text
View/download PDF

24. Nonmyeloablative Allogeneic Transplantation in First Remission for Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia with Post-Transplantation Cyclophosphamide: Outcomes By Receipt of Pre-Transplant Blinatumomab

Author

Webster, Jonathan, primary, Smith, B. Douglas, additional, DeZern, Amy E., additional, Ambinder, Alexander J., additional, Levis, Mark, additional, Showel, Margaret M., additional, Prince, Gabrielle T., additional, Gondek, Lukasz P., additional, Ghiaur, Gabriel, additional, Dalton, William Brian, additional, Hourigan, Christopher S., additional, Jain, Tania, additional, Gladstone, Douglas E, additional, Luznik, Leo, additional, Imus, Philip H., additional, Bolanos-Meade, Javier, additional, Fuchs, Ephraim J., additional, Gocke, Christian B., additional, Ali, Abbas Abbas, additional, Huff, Carol Ann, additional, Borrello, Ivan M., additional, Swinnen, Lode J., additional, Wagner-Johnston, Nina D., additional, Ambinder, Richard F., additional, Jones, Richard J., additional, and Gojo, Ivana, additional

Published
2021
Full Text
View/download PDF

26. Additional file 1 of Safety and antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with multiple myeloma

Author

Greenberg, Ross S., Ruddy, Jake A., Boyarsky, Brian J., Werbel, William A., Garonzik-Wang, Jacqueline M., Segev, Dorry L., and Imus, Philip H.

Subjects
body regions, fungi, skin and connective tissue diseases
Abstract

Additional file 1: Supplemental Figure 1. Local site and systemic adverse reactions in 44 patients with multiple myeloma within 7 days of dose 1 and dose 2 of the SARS-CoV-2 mRNA vaccine. Supplemental Table 1. Anti-SARS-CoV-2 RBD antibody titer of 44 patients multiple myeloma 1 month after two-dose SARS-CoV-2 mRNA vaccination by demographics and clinical characteristics.

Published
2021
Full Text
View/download PDF

27. Reduced-Intensity Induction with Dasatinib Vs. Hypercvad + 2nd Generation TKIs with MRD-Guided Follow-up Therapy Leads to Comparable Rates of MRD-Negative Remission While Reducing Transfusions and Neutropenia in Ph+ ALL

Author

Webster, Jonathan, Tsai, Hua-Ling, Gehrie, Eric, Jain, Tania, Hourigan, Christopher S., Dalton, William Brian, Prince, Gabrielle T., Gondek, Lukasz P., Ghiaur, Gabriel, DeZern, Amy E., Showel, Margaret M., Gojo, Ivana, Gladstone, Douglas E, Imus, Philip H., Bolanos-Meade, Javier, Luznik, Leo, Fuchs, Ephraim J., Gocke, Christian B., Ali, Abbas Abbas, Huff, Carol Ann, Borrello, Ivan M., Swinnen, Lode J., Wagner-Johnston, Nina D., Ambinder, Richard F., Jones, Richard J., Smith, B. Douglas, and Levis, Mark

Published
2020
Full Text
View/download PDF

29. Allogeneic Transplantation for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia with Post-Transplantation Cyclophosphamide: Assessing the Importance of Conditioning Regimen, Donor Choice, and Tyrosine Kinase Inhibitor Use

Author

Webster, Jonathan, primary, Luznik, Leo, additional, Tsai, Hua-Ling, additional, Imus, Philip H., additional, DeZern, Amy E., additional, Pratz, Keith W., additional, Levis, Mark, additional, Gojo, Ivana, additional, Showel, Margaret M., additional, Prince, Gabrielle T., additional, Bolanos-Meade, Javier, additional, Gondek, Lukasz P., additional, Ghiaur, Gabriel, additional, Dalton, William Brian, additional, Jain, Tania, additional, Fuchs, Ephraim J., additional, Gladstone, Douglas E, additional, Gocke, Christian B., additional, Ali, Abbas Abbas, additional, Huff, Carol Ann, additional, Borrello, Ivan M., additional, Swinnen, Lode J., additional, Wagner-Johnston, Nina D., additional, Ambinder, Richard F., additional, Jones, Richard J., additional, and Smith, B. Douglas, additional

Published
2020
Full Text
View/download PDF

31. Phase II study of rituximab given in conjunction with standard chemotherapy in primary central nervous system lymphoma (PCNSL): a trial of the ECOG-ACRIN cancer research group (E1F05)

Author

Swinnen, Lode J., primary, O’Neill, Anne, additional, Imus, Philip H., additional, Gujar, Sachin, additional, Schiff, David, additional, Kleinberg, Lawrence R., additional, Advani, Ranjana H., additional, Dunbar, Erin M., additional, Moore, Dennis, additional, and Grossman, Stuart A., additional

Published
2017
Full Text
View/download PDF

32. Allogeneic transplantation for Ph+acute lymphoblastic leukemia with posttransplantation cyclophosphamide

Author

Webster, Jonathan A., Luznik, Leo, Tsai, Hua-Ling, Imus, Philip H., DeZern, Amy E., Pratz, Keith W., Levis, Mark J., Gojo, Ivana, Showel, Margaret M., Prince, Gabrielle, Bolaños-Meade, Javier, Gondek, Lukasz P., Ghiaur, Gabriel, Dalton, W. Brian, Jain, Tania, Fuchs, Ephraim J., Gladstone, Douglas E., Gocke, Christian B., Ali, Syed Abbas, Huff, Carol Ann, Borrello, Ivan M., Swinnen, Lode, Wagner-Johnston, Nina, Ambinder, Richard F., Jones, Richard J., and Smith, B. Douglas

Abstract

Allogeneic blood or marrow transplantation (alloBMT) is standard of care for adults with Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ALL) in first complete remission (CR1). The routine pretransplant and posttransplant use of tyrosine kinase inhibitors (TKIs) has dramatically improved outcomes, but the optimal conditioning regimen, donor type, and TKI remain undefined. The bone marrow transplant database at Johns Hopkins was queried for adult patients with de novo Ph+ALL who received alloBMT using posttransplantation cyclophosphamide (PTCy) as a component of graft-versus-host disease (GVHD) prophylaxis from 2008 to 2018. Among transplants for Ph+ALL, 69 (85%) were performed in CR1, and 12 (15%) were performed in second or greater remission (CR2+). The majority of transplants (58%) were HLA haploidentical. Nearly all patients (91.4%) initiated TKI posttransplant. For patients in CR1, the 5-year relapse-free survival (RFS) was 66%. The use of nonmyeloablative conditioning, absence of measurable residual disease (MRD) according to flow cytometry at transplant, and the use of dasatinib vs imatinib at diagnosis were associated with improved overall survival (OS) and RFS. Neither donor type nor recipient age ≥60 years affected RFS. When analyzing all transplants, alloBMT in CR1 (vs CR2+) and the absence of pretransplant MRD were associated with improved RFS. Most relapses were associated with the emergence of kinase domain mutations. The cumulative incidence of grade 3 to 4 acute GVHD at 1 year was 9%, and moderate to severe chronic GVHD at 2 years was 8%. Nonmyeloablative alloBMT with PTCy for Ph+ALL in an MRD-negative CR1 after initial treatment with dasatinib yields favorable outcomes.

Published
2020
Full Text
View/download PDF

35. Reduced-Intensity Induction with Dasatinib Vs. Hypercvad + 2ndGeneration TKIs with MRD-Guided Follow-up Therapy Leads to Comparable Rates of MRD-Negative Remission While Reducing Transfusions and Neutropenia in Ph+ ALL

Author

Webster, Jonathan, Tsai, Hua-Ling, Gehrie, Eric, Jain, Tania, Hourigan, Christopher S., Dalton, William Brian, Prince, Gabrielle T., Gondek, Lukasz P., Ghiaur, Gabriel, DeZern, Amy E., Showel, Margaret M., Gojo, Ivana, Gladstone, Douglas E, Imus, Philip H., Bolanos-Meade, Javier, Luznik, Leo, Fuchs, Ephraim J., Gocke, Christian B., Ali, Abbas Abbas, Huff, Carol Ann, Borrello, Ivan M., Swinnen, Lode J., Wagner-Johnston, Nina D., Ambinder, Richard F., Jones, Richard J., Smith, B. Douglas, and Levis, Mark

Abstract

Background:Reduced-intensity induction (RII) with imatinib yields comparable outcomes to HyperCVAD with imatinib with fewer induction deaths and an improved CR rate in Ph+ ALL (Chalandon. Blood. 2015). Dasatinib with steroids also produces excellent responses with little toxicity (Foa. Blood. 2011). Allogeneic bone marrow transplant (AlloBMT) remains the goal of therapy in Ph+ ALL based on contemporary trials with TKIs demonstrating improved survival in patients transplanted in CR1, and we have shown that transplant following induction with dasatinib yields better outcomes than with imatinib. Thus we implemented RII with dasatinib for the treatment of Ph+ ALL and compared to patients who received HyperCVAD with a 2nd generation TKI.

Published
2020
Full Text
View/download PDF

36. “Allogeneic blood or marrow transplant with non-myeloablative conditioning and high dose cyclophosphamide-based graft-versus-host disease prophylaxis for secondary central nervous system lymphoma”

Author

Sterling, Cole H, Tsai, Hua-Ling, Holdhoff, Matthias, Bolaños-Meade, Javier, Luznik, Leo, Fuchs, Ephraim J, Huff, Carol Ann, Gocke, Christian B, Ali, Syed Abbas, Borrello, Ivan M, Varadhan, Ravi, Jones, Richard J, Gladstone, Douglas E, Ambinder, Richard F, Wagner-Johnston, Nina, Swinnen, Lode J, and Imus, Philip H

Abstract

•We reviewed outcomes in 20 patients with secondary CNS lymphoma undergoing alloBMT.•All received non-myeloablative conditioning with post-transplant cyclophosphamide.•Prolonged disease-free survival was achieved in ∼50% of patients.•Myeloablative conditioning and CNS radiotherapy were not required for remission.

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results